ENTA CIK: 1177648

Enanta Pharmaceuticals, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
319
FY22:
312
FY23:
423
FY24:
300
FY25:
204
(positive)
Change from FY21 to FY25
millions USD
FY21:
120
FY22:
63.7
FY23:
39.5
FY24:
76.8
FY25:
76.4
Total assets
Change from FY21 to FY25
millions USD
FY21:
439
FY22:
375
FY23:
462
FY24:
377
FY25:
281

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
36.2
FY22:
29.8
FY23:
62.8
FY24:
57.5
FY25:
48.6
(negative)
Change from FY21 to FY25
millions USD
FY21:
3.19
FY22:
24.2
FY23:
183
FY24:
190
FY25:
167
(positive)
Change from FY21 to FY25
millions USD
FY21:
399
FY22:
321
FY23:
217
FY24:
129
FY25:
64.7
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
439
FY22:
375
FY23:
462
FY24:
377
FY25:
281

All amounts in millions USD Data source:SEC EDGAR